These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2251892)

  • 1. [The formation of a test system for assessing the safety of different types of pertussis preparations: their cytotoxic action on mouse thymocytes in vitro].
    Nuriddinova NR; Lapaeva IA; Guseva MV; Vafakulov BKh
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Jul; (7):50-4. PubMed ID: 2251892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The development of a new generation of pertussis vaccine].
    Chuprinina RP; Bychenko BD; Smirnov VD; Maksiutov RV; Eglit IuKh
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Oct; (10):89-94. PubMed ID: 2075771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Improvement in the laboratory methods of assessing the safety of the of the pertussis component of DPT vaccine adsorbed].
    Chuprinina RP; Il'nitskaia EA; Polikar A; Vŭlchev V; Mikhaĭlova V; Niedermayer N; Pruchová J; Kardymowics B; Kudelski Z; Rymkewics D
    Zh Mikrobiol Epidemiol Immunobiol; 1992 Jan; (1):28-33. PubMed ID: 1414103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of pharmacological screening for characterizing the toxicity of pertussis vaccines].
    Zakharova NS; Koval'skaia SIa; Ozeretskovskiĭ NA; Shepeleva IB; Britsina MV; Lobanova AN; Ozeretskovskaia MN
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Jun; (6):50-3. PubMed ID: 2220220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased levels of active pertussis toxin may aid a pertussis vaccine to pass the mouse body weight gain test.
    Horiuchi Y; Takahashi M; Asada S; Ishida S
    Biologicals; 1994 Sep; 22(3):243-8. PubMed ID: 7811458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acellular pertussis vaccines: evaluation of reversion in a nude mouse model.
    Quentin-Millet MJ; Arminjon F; Danve B; Cadoz M; Armand J
    J Biol Stand; 1988 Apr; 16(2):99-108. PubMed ID: 3259580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A polyvalent complex of Bordetella pertussis antigens as the basis for an acellular pertussis vaccine].
    Zakharova NS; Shmeleva EI; Remova TN; Bazhanova IG; Ozeretskovskaia MN; Mertsalova NU; Britsina MV; Ermolova EV; Zaĭtsev EM
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (3):70-2. PubMed ID: 9304336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children.
    Pichichero ME; Badgett JT; Rodgers GC; McLinn S; Trevino-Scatterday B; Nelson JD
    Pediatr Infect Dis J; 1987 Apr; 6(4):352-63. PubMed ID: 3495775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The safety and protective properties of a new cell-free pertussis vaccine in animal trials].
    Bazhanova IG; Remova TN; Ozeretskovskaia MN; Shmeleva EI; Mertsalova NU; Sukhinova EE; Chuprinina RP; Bulk VF; Semina IE; Koval'skaia SIa
    Zh Mikrobiol Epidemiol Immunobiol; 1994; (1):40-5. PubMed ID: 8184612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preclinical studies of an adsorbed diphtheria-tetanus-pertussis vaccine (ADTP-vaccine) with acellular pertussis component].
    Zaĭtsev EM; Britsina MV; Bazhanova IG; Mertsalova NU; Ozeretskovskaia MN; Ermolova EV; Plekhanova NG; Mikhaĭlova NA; Kolyshkin VA; Zverev VV
    Zh Mikrobiol Epidemiol Immunobiol; 2013; (6):44-9. PubMed ID: 24605674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of purified components of Bordetella pertussis in the weight gain test for the toxicity testing of pertussis vaccines.
    Redhead K; Seagroatt V
    J Biol Stand; 1986 Jan; 14(1):57-65. PubMed ID: 2870067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acellular and whole cell pertussis vaccines protect against the lethal effects of intracerebral challenge by two different T-cell dependent humoral routes.
    Wiertz EJ; Walvoort HC; Van Loveren H; Van Straaten-Van De Kappelle I; Van Der Gun JW; Kreeftenberg JG
    Biologicals; 1990 Jul; 18(3):173-80. PubMed ID: 2257130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis.
    Vandebriel RJ; Gremmer ER; Vermeulen JP; Hellwig SM; Dormans JA; Roholl PJ; Mooi FR
    Vaccine; 2007 Mar; 25(12):2346-60. PubMed ID: 17224216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and potency of an acellular pertussis vaccine composed of pertussis toxin, filamentous hemagglutinin, and pertactin.
    Sheu GC; Wo YY; Yao SM; Chou FY; Hsu TC; Ju CL; Cheng Y; Chang SN; Lu CH
    J Microbiol Immunol Infect; 2001 Dec; 34(4):243-51. PubMed ID: 11825003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children.
    Marcinak JF; Ward M; Frank AL; Boyer KM; Froeschle JE; Hosbach PH
    Am J Dis Child; 1993 Mar; 147(3):290-4. PubMed ID: 8438810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
    Halperin SA; Scheifele D; Barreto L; Pim C; Guasparini R; Medd L; Meekison W; Eastwood BJ
    Pediatr Infect Dis J; 1999 Sep; 18(9):772-9. PubMed ID: 10493336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
    Matheson AJ; Goa KL
    Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.